Venus Remedies Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Venus Remedies zahlt derzeit keine Dividende.

Wichtige Informationen

Dividendenausschüttung

Ausschüttungsquote

Durchschnittlicher Branchenertrag	0.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	₹21.31
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Jun 14

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Jun 13

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 14

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Mar 30

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Feb 24

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Feb 01

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Nov 16

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

Mar 11

We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Jan 14

Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 23

Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

Sep 22

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von VENUSREM in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von VENUSREM gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Venus Remedies Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von VENUSREM im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (VENUSREM)	0%
Untere 25 % des Marktes (IN)	0.3%
Markt Top 25 % (IN)	1.1%
Branchendurchschnitt (Pharmaceuticals)	0.8%
Analystenprognose in 3 Jahren (VENUSREM)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von VENUSREM im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von VENUSREM im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: VENUSREM zahlt keine nennenswerte Dividende für den Markt Indian.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da VENUSREM keine Ausschüttungen gemeldet hat.

Venus Remedies Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Now 27% overvalued after recent price rise

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹21.31 (vs ₹19.87 in FY 2023)

Venus Remedies Limited to Report Q4, 2024 Results on May 30, 2024

Investor sentiment improves as stock rises 16%

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Third quarter 2024 earnings released: EPS: ₹5.13 (vs ₹2.46 in 3Q 2023)

Venus Remedies Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: EPS: ₹7.44 (vs ₹3.99 in 2Q 2023)

Investor sentiment improves as stock rises 23%

Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Venus Remedies Limited to Report Q2, 2024 Results on Nov 09, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Now 20% undervalued after recent price drop

Venus Remedies Limited Receives Marketing Approval from the Philippines for Six Key Chemotherapy Drugs

Investor sentiment deteriorates as stock falls 15%

New minor risk - Profit margin trend

Venus Remedies Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings released: EPS: ₹19.87 (vs ₹30.86 in FY 2022)

Venus Remedies Limited, Annual General Meeting, Aug 24, 2023

Investor sentiment improves as stock rises 15%

Venus Remedies Limited Receives Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities

Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Full year 2023 earnings released: EPS: ₹19.88 (vs ₹30.86 in FY 2022)

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 20%

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: ₹2.46 (vs ₹4.22 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹3.99 (vs ₹17.32 in 2Q 2022)

First quarter 2023 earnings released: EPS: ₹5.16 (vs ₹8.86 in 1Q 2022)

Venus Remedies Limited to Report Q2, 2023 Results on Nov 14, 2022

Venus Remedies Limited, Annual General Meeting, Aug 23, 2022

Venus Remedies Limited to Report Q1, 2023 Results on Jul 30, 2022

Now 21% undervalued after recent price drop

Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Now 25% undervalued after recent price drop

Chairman recently bought ₹28m worth of stock

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Now 19% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹30.86 (vs ₹50.05 in FY 2021)

Venus Remedies Limited Appoints Akshansh Chaudhary as Additional Director (Whole Time Director)

Investor sentiment improved over the past week

Venus Remedies Limited to Report Q4, 2022 Results on May 27, 2022

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Second quarter 2022 earnings released: EPS ₹17.32 (vs ₹10.55 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS ₹8.86 (vs ₹6.08 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹50.04 (vs ₹8.10 loss in FY 2020)

Venus Remedies Limited announced that it has received INR 137.52425 million in funding

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

New 90-day high: ₹228

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹9.44 (vs ₹0.78 loss in 3Q 2020)

New 90-day high: ₹184

We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

New 90-day high: ₹165

Investor sentiment improved over the past week

Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Venus Remedies Limited to Report Q3, 2021 Results on Feb 15, 2021

Venus Remedies Limited, Annual General Meeting, Dec 02, 2020

Venus Remedies Limited to Report Q2, 2021 Results on Nov 06, 2020

New 90-day high: ₹150